PTEN and p53 expression in primary ovarian carcinomas: Immunohistochemical study and discussion of pathogenetic mechanisms

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 1, 2006, Pages 254-258

  Gomes, C P ^a   Andrade, L A L A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Immunohistochemistry; Ovarian carcinomas; p53; Pathogenesis; PTEN

Indexed keywords

BIOLOGICAL MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOMETRIOID CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORPHOLOGY; MUCINOUS CARCINOMA; OVARY CARCINOMA; PARAMETER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROSA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645360886     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00306.x     Document Type: Article

References (30)

1. Shayesteh L Lu Y Kuo WL et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999 21 99 102.
2. Zhang L Yang N Katsaros D. The oncogene phosphatidylinositol 3′kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res 2003 63 4225 31.
3. Schrami P Schwerdtfeger G Burkhalter F. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as critical oncogene target in ovarian carcinoma. Am J Pathol 2003 163 985 92.
4. Auersperg N Ota T Mitchell GWE. Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. Int J Gynecol Cancer 2002 12 691 703.
5. Mutter GL Lin MC Fitzgerald JT. Changes in endometrial PTEN expression throughout the human menstrual cycle. Int J Clin Endocrinol Metab 2000 85 2334 8.
6. Lee JO Yang H Georgescu MM. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999 99 323 34.
7. Mayo LD Donner DB. The PTEN, MDM2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002 27 462 7.
8. Hofseth LJ Hussain SP Harris CC. P53: 25 years after its discovery. Trends Pharmocol Sci 2004 25 177 81.
9. Mhawech P Kinkel K Vlastos G. Ovarian carcinomas in endometriosis: an immunohistochemical and comparative genomic hybridization study. Int J Gynecol Pathol 2002 21 401 6.
10. Tashiro H Blazes MS Wu R. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997 57 3935 40.
11. Maxwell GL Risinger JI Tong B. Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers. Gynecol Oncol 1998 70 13 6.
12. Mutter LG. PTEN, a protean tumor suppressor. Am J Pathol 2001 158 1895 8.
13. Han B Dong Z Liu Y. Regulation of constitutive expression of mouse PTEN by the 5′ untranslated region. Oncogene 2003 22 5325 37.
14. Jones PA Laird PW. Cancer epigenetics comes of age. Nat Genet 1999 21 163 7.
15. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004 444 213 23.
16. Kimura F Watanabe J Hata H. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol 2004 130 161 8
17. Martini M Ciccarone M Garganese G. Possible involvement of hMLH1, p16 ink4alpha and PTEN in the malignant transformation of endometriosis. Int J Cancer 2002 102 398 406.
18. Sato N Tsunoda H Nishida M et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000 60 7052 6.
19. Erzen M Rakar S Klancar B. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 2001 83 100 8.
20. Giudice LC Kao LC. Endometriosis. Lancet 2004 364 1789 99.
21. Guzeloglu-Kayisli O Kayaisli UA Al-Rejjal R et al. Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab 2003 88 5017 26.
22. Moutsatsou P Sekeris CE. Steroids receptors in the uterus: implications in endometriosis. Ann N Y Acad Sci 2003 997 209 22.
23. Shoman N Klassen S Mcfadden A et al. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 2005 18 250 9.
24. Simoncini T Hafezi-Moghadam A Brazil DP et al. Interactions of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000 407 538 41.
25. Campisi J. Replicative senescence: an old lives' tale? Cell 1996 84 497 500.
26. Itahana K Dimri G Campisi J. Regulation of cellular senescence by p53. Eur J Biochem 2001 268 2784 91.
27. Cao L Li W Kim S. Senescence, aging and malignant transformation mediated by p53 in mice lacking the BRCA1 full-length isoform. Genes Dev 2003 17 201 13.
28. Edmondson RJ Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer 2001 11 423 9.
29. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 1999 13 295 308.
30. Sinal A Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000 60 6788 93.